| Identification | Back Directory | [Name]
PR104 | [CAS]
851627-62-8 | [Synonyms]
PR104
PR-104/104A
PR 104;PR104
GZSOKPMDWVRVMG-UHFFFAOYSA-N
2-[N-(2-bromoethyl)-2,4-dinitro-6-(2-phosphonooxyethylcarbamoyl)anilino]ethyl methanesulfonate
2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate
Benzamide, 2-[(2-bromoethyl)[2-[(methylsulfonyl)oxy]ethyl]amino]-3,5-dinitro-N-[2-(phosphonooxy)ethyl]- | [Molecular Formula]
C14H20BrN4O12PS | [MDL Number]
MFCD25976844 | [MOL File]
851627-62-8.mol | [Molecular Weight]
579.27 |
| Hazard Information | Back Directory | [Uses]
PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A[1]. | [in vivo]
PR-104 (0.56 mmol/kg; i.v. or i.p.; 0~2 hours) makes the plasma area under the curve. PR-104 (0.23 mmol/kg; i.p.; 100 days) shows antitumor activity[1]. | Animal Model: | CD-1nu/nu mice | | Dosage: | 0.56 mmol/kg (Pharmacokinetics Analysis) | | Administration: | I.v. or i.p. | | Result: | The plasma area under the curve.
|
| Animal Model: | CD1-Foxn1nu mice | | Dosage: | 0.23 mmol/kg | | Administration: | I.p. | | Result: | Showed antitumor activity.
|
| [References]
[1] Patterson AV, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932. DOI:10.1158/1078-0432.CCR-07-0478 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|